Histopathological outcome predictors of quiescence/remission in inflammatory bowel diseases: A need being addressed.
作者信息
Villanacci Vincenzo, Bassotti Gabrio
机构信息
Institute of Pathology, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Gastroenterology and Hepatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
出版信息
United European Gastroenterol J. 2024 Nov;12(9):1153-1154. doi: 10.1002/ueg2.12678. Epub 2024 Oct 24.
Abstract
摘要
相似文献
1
Histopathological outcome predictors of quiescence/remission in inflammatory bowel diseases: A need being addressed.炎症性肠病静止/缓解的组织病理学结果预测因素：一个正在被解决的需求。
United European Gastroenterol J. 2024 Nov;12(9):1153-1154. doi: 10.1002/ueg2.12678. Epub 2024 Oct 24.
2
Epithelial neutrophil localization and tight junction Claudin-2 expression are innovative outcome predictors in inflammatory bowel disease.上皮中性粒细胞定位和紧密连接 Claudin-2 表达是炎症性肠病的创新性预后预测指标。
United European Gastroenterol J. 2024 Nov;12(9):1155-1166. doi: 10.1002/ueg2.12677. Epub 2024 Oct 3.
3
Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission.炎症性肠病缓解期患者肠道微生物群失调。
Microbiol Spectr. 2022 Jun 29;10(3):e0061622. doi: 10.1128/spectrum.00616-22. Epub 2022 May 9.
4
Claudin-2: A marker for a better evaluation of histological mucosal healing in inflammatory bowel diseases.Claudin-2：一种用于更好评估炎症性肠病组织学黏膜愈合的标志物。
Dig Liver Dis. 2025 Apr;57(4):827-832. doi: 10.1016/j.dld.2024.08.001. Epub 2024 Aug 17.
5
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.在炎症性肠病儿科患者中使用维得利珠单抗的安全性和有效性：一项观察性多中心西班牙研究。
Eur J Pediatr. 2021 Sep;180(9):3029-3038. doi: 10.1007/s00431-021-04063-6. Epub 2021 Apr 20.
6
Biochemical Modulators of Tight Junctions (TJs): Occludin, Claudin-2 and Zonulin as Biomarkers of Intestinal Barrier Leakage in the Diagnosis and Assessment of Inflammatory Bowel Disease Progression.紧密连接（TJs）的生化调节剂：闭锁蛋白、Claudin-2 和紧密连接蛋白作为肠道屏障通透性的生物标志物在炎症性肠病进展的诊断和评估中的作用。
Molecules. 2024 Sep 26;29(19):4577. doi: 10.3390/molecules29194577.
7
Predictors of infliximab-induced deep remission in treatment-naïve patients with isolated small bowel Crohn's disease.初治孤立性小肠克罗恩病患者诱导英夫利昔单抗深度缓解的预测因素。
Scand J Gastroenterol. 2021 Dec;56(12):1422-1426. doi: 10.1080/00365521.2021.1971759. Epub 2021 Aug 30.
8
Outcomes of placebo therapy in inflammatory bowel disease.安慰剂疗法在炎症性肠病中的疗效。
Inflamm Bowel Dis. 2006 Apr;12(4):328-33. doi: 10.1097/01.MIB.0000215094.69869.2e.
9
Preconception counseling of females with inflammatory bowel disease.炎症性肠病女性的孕前咨询。
Best Pract Res Clin Gastroenterol. 2020 Feb-Apr;44-45:101666. doi: 10.1016/j.bpg.2020.101666. Epub 2020 Jan 16.
10
Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation.缓解期和加重期炎症性肠病患者的白细胞介素-18及其结合蛋白
Isr Med Assoc J. 2007 Jul;9(7):504-8.
本文引用的文献
1
Epithelial neutrophil localization and tight junction Claudin-2 expression are innovative outcome predictors in inflammatory bowel disease.上皮中性粒细胞定位和紧密连接 Claudin-2 表达是炎症性肠病的创新性预后预测指标。
United European Gastroenterol J. 2024 Nov;12(9):1155-1166. doi: 10.1002/ueg2.12677. Epub 2024 Oct 3.
2
Claudin-2: A marker for a better evaluation of histological mucosal healing in inflammatory bowel diseases.Claudin-2：一种用于更好评估炎症性肠病组织学黏膜愈合的标志物。
Dig Liver Dis. 2025 Apr;57(4):827-832. doi: 10.1016/j.dld.2024.08.001. Epub 2024 Aug 17.
3
Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease.联合靶向治疗炎症性肠病的当前证据
J Can Assoc Gastroenterol. 2023 Sep 26;7(1):22-29. doi: 10.1093/jcag/gwad032. eCollection 2024 Feb.
4
Letter: The importance of histological assessment-a further stride in STRIDE.信函：组织学评估的重要性——STRIDE的又一进展。
Aliment Pharmacol Ther. 2023 Dec;58(11-12):1244-1245. doi: 10.1111/apt.17717.
5
Inflammatory Bowel Diseases: Does One Histological Score Fit All?炎症性肠病：一种组织学评分适用于所有情况吗？
Diagnostics (Basel). 2023 Jun 19;13(12):2112. doi: 10.3390/diagnostics13122112.
6
Simplified Histologic Mucosal Healing Scheme (SHMHS) for inflammatory bowel disease: a nationwide multicenter study of performance and applicability.简化的炎症性肠病组织学黏膜愈合方案（SHMHS）：一项全国多中心的性能和适用性研究。
Tech Coloproctol. 2022 Sep;26(9):713-723. doi: 10.1007/s10151-022-02628-7. Epub 2022 Jun 1.
7
Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art.炎症性肠病患者的组织学评分：现状
J Clin Med. 2022 Feb 11;11(4):939. doi: 10.3390/jcm11040939.
8
Usefulness of Different Pathological Scores to Assess Healing of the Mucosa in Inflammatory Bowel Diseases: A Real Life Study.不同病理评分在评估炎症性肠病黏膜愈合中的作用：真实世界研究。
Sci Rep. 2017 Jul 28;7(1):6839. doi: 10.1038/s41598-017-07338-x.
9
Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings.由内镜梅奥子评分定义的完全黏膜愈合，通过新型高清结肠镜检查和改良组织学分级仍显示存在异常。
Endoscopy. 2015 Aug;47(8):726-34. doi: 10.1055/s-0034-1391863. Epub 2015 Mar 31.
10
Reproducibility of histological assessments of disease activity in UC.UC 中疾病活动的组织学评估的可重复性。
Gut. 2015 Nov;64(11):1765-73. doi: 10.1136/gutjnl-2014-307536. Epub 2014 Oct 30.
Zotero 插件